利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.027 秒)

    Sustained release intraocular drug delivery systems
    1.
    发明申请
    Sustained release intraocular drug delivery systems 审中-公开
    持续释放眼内药物递送系统

    公开(公告)号：US20060182783A1

    公开(公告)日：2006-08-17

    申请号：US11370301

    申请日：2006-03-08

    申请人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

    发明人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

    IPC分类号： A61K48/00 ,  A61F2/00

    CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40 ,  A61K48/0041

    摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent contains a component selected from the group consisting of anti-angiogenesis peptides and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成大分子治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂含有选自抗血管生成肽和核酸试剂的组分。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Macromolecule-containing sustained release intraocular implants and related methods
    3.
    发明申请
    Macromolecule-containing sustained release intraocular implants and related methods 审中-公开
    含大分子的持续释放眼内植入物及相关方法

    公开(公告)号：US20050281861A1

    公开(公告)日：2005-12-22

    申请号：US11116698

    申请日：2005-04-27

    申请人： Patrick Hughes ,  Tom Malone ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    发明人： Patrick Hughes ,  Tom Malone ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    IPC分类号： A61F2/00 ,  A61F9/00 ,  A61K9/00 ,  A61K9/16 ,  A61K31/724 ,  A61K39/395 ,  A61K47/34 ,  A61K47/40 ,  A61K47/48 ,  A61K48/00

    CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40

    摘要： Biocompatible intraocular drug delivery systems include a non-neurotoxic macromolecule therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The macromolecule therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis agents, ocular hemorrhage treatment agents, non-steroidal anti-inflammatory agents, growth factor inhibitors (such as VEGF inhibitors), growth factors, cytokines, antibodies, oligonucleotide aptamers, siRNA molecules and antibiotics. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括非神经毒性大分子治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 大分子治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可保留其三维结构，或者治疗剂可具有改变的三维结构，但保持其治疗活性。 治疗剂可以选自抗血管生成剂，眼出血治疗剂，非甾体抗炎剂，生长因子抑制剂（例如VEGF抑制剂），生长因子，细胞因子，抗体，寡核苷酸适体，siRNA 分子和抗生素。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Anti-angiogenic sustained release intraocular implants and related methods
    4.
    发明申请
    Anti-angiogenic sustained release intraocular implants and related methods 审中-公开
    抗血管生成持续释放眼内植入物及相关方法

    公开(公告)号：US20070059336A1

    公开(公告)日：2007-03-15

    申请号：US11364687

    申请日：2006-02-27

    申请人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    发明人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    IPC分类号： A61K38/18 ,  A61K39/395

    CPC分类号： A61K48/0041 ,  A61K9/0051

    摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis peptides, hormones and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂可以选自抗血管生成肽，激素和核酸试剂。 植入物可以置于眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。